Newly discovered mechanism regulates microglial characteristics in early brain development
Researchers at University of Tsukuba have discovered a novel mechanism involved in brain development. They found that small ...
NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
February 6, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has ...